Steroid Hormone Dependent Inflammation and Regulation in the Endometrium in Women with Dysfunctional Menstrual Cycles: Is There a Role for Toll-Like Receptor Activation via PAMPs and DAMPs?

Elise S Pelzer1*, Flavia Huygens1 and Kenneth W Beagley1

1School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Faculty of Science and Technology, Queensland University of Technology, Brisbane, Queensland, Australia
2The Wesley Research Institute, Women's Health Laboratory, The Wesley Hospital, Auchenflower, Queensland, Australia

Summary Sentence
The role of microbial and immunological menstrual cycle dependent changes within the endometrium may provide insight into the underlying causes of dysfunctional menstrual cycles.

Abstract
The ovarian steroid hormones control cyclic cellular proliferation, differentiation, inflammatory cell recruitment, apoptosis, tissue degradation and regeneration associated with the menstrual cycle as well as the response to pathogen challenge. Women with dysfunctional menstrual cycles (menorrhagia and dysmenorrhea) exhibit altered cytokine and prostaglandin expression in the endometrium implying ongoing recruitment of innate immune mediators. Activation of TLRs by endogenous and/or exogenous ligands caused by cell damage resulting from ongoing inflammation, endogenous microbiota or dysbiosis may contribute to the inflammatory symptoms associated with these conditions. The role of the upper genital tract endogenous microbiota in promoting genital tract homeostasis through possible promotion of re-epithelialization or anti-inflammatory mediators warrants further investigation.

Keywords: Menorrhagia; Dysmenorrhea; Toll-like receptor; Pathogen associated molecular patterns; Damage associate molecular patterns

Dysfunctional Menstrual Cycles – Menorrhagia and Dysmenorrhea
Primary menorrhagia represents dysfunctional menstrual bleeding with a menstrual loss in excess of 80 millilitres per cycle, in the absence of abnormal uterine pathology. This condition affects between 10-30% of reproductive aged women [1]. Similar to primary menorrhagia, no identifiable uterine abnormality is detected in women with primary dysmenorrhea. Primary dysmenorrhea is characterized by painful menstrual cramps as a result of abnormal uterine contractility [2]. Reduced blood flow due to ischemia is correlated with more severe pain. Together, these conditions affect up to 50% of women during reproductive life and result in significant morbidity, incapacitation and lost work days in some 10% of sufferers. Half of all women who have a hysterectomy for menorrhagia before age 60 years have an anatomically normal uterus [3].

Steroid Hormones and the Menstrual Cycle
Cyclic tissue remodelling in the endometrium occurs under the influence of fluctuating levels of the ovarian steroid hormones estradiol and progesterone [4,5] (Figure 1). Steroid receptors for estrogens, progestins and androgens have been reported to fluctuate throughout the menstrual cycle. The ovarian steroid hormones modulate the ability of each to respond to the other and other hormone–dependent factors [6]. Both estrogen and progesterone receptors peak during the second half of the proliferative phase of the cycle, and decline during the secretory phase of the cycle in response to progesterone, though to varying degrees for each isoform [7-10]. Androgen receptor expression decreases from the proliferative until the mid-secretory phase and is undetectable by the late secretory phase [11].

Menstrual phase
The menstrual phase of the cycle is characterized by progesterone withdrawal. The endometrial response to progesterone withdrawal preceding menstruation involves mediators of apoptosis, haemostasis and wound healing. An influx of inflammatory cells into the endometrium occurs prior to menstruation.

Prostaglandins are key mediators in menstrual cycle processes [12]. Prostaglandins are regulated by progesterone, and are implicated in menstruation [13]. Prostaglandins promote uterine contraction, and vasoconstriction leading to hypoxia, ischemia and pain [14]. Prostaglandins are eicosanoid cyclooxygenase (COX) metabolites of arachidonic acid, promoting angiogenesis by binding to specific cell receptors. Dysregulation in biosynthesis or signalling of the prostaglandin receptors can result in abnormal vasculature leading to dysfunctional uterine bleeding. COX-2 is up-regulated during the peri-menstrual period [15]. Matrix metalloproteases (MMPs) have been implicated in the irreversible tissue breakdown associated with menstruation in response to progesterone withdrawal during the pre-menstrual period [16].

Proliferative phase
Estrogen dominance results in significant changes in growth factor secretions and endometrial regeneration causing increased endometrial height. Estradiol stimulates the expression of epidermal growth factor

*Corresponding author: Elise S Pelzer, School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Faculty of Science and Technology, Queensland University of Technology, Brisbane, Queensland, Australia.

Received: June 23, 2016; Accepted: July 29, 2016; Published: August 09, 2016

Citation: Pelzer ES, Huygens F, Beagley KW (2016) Steroid Hormone Dependent Inflammation and Regulation in the Endometrium in Women with Dysfunctional Menstrual Cycles: Is There a Role for Toll-Like Receptor Activation via PAMPs and DAMPs? J Microb Biochem Technol 8: 344-357. doi: 10.4172/1948-5948.1000307

Copyright: © 2016 Pelzer ES, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Secretory phase

The secretory phase of the menstrual cycle is characterized by progesterone dominance. Proliferation ceases and endometrial differentiation occurs, however the endometrial height is fixed due to growth inhibition by progesterone interference with estrogen receptor expression [19,20]. Progesterone levels peak in the estrogen primed endometrium resulting in increased inflammatory cell infiltrates and commencement of decidualization.

Steroid Hormones and Immunity

Mucosal immunity within the female genital tract is also regulated by the steroid hormones. Cyclic changes in estradiol and progesterone concentrations result in controlled recruitment of immune cell populations, antigen presentation and cytokine secretion [6]. The steroid hormones influence both the innate and the adaptive immune responses, contributing to the immediate non-specific response to pathogen associated molecular patterns (PAMPs) and the specific but delayed humoral and cell mediated antigen presentation in adaptive immunity [21]. Estrogens enhance the humoral immune response whereas progesterones suppress the proliferative capacity of lymphocytes within the endometrium; increasing infection risk [22-24]. Androgens inhibit both cell-mediated and humoral immunity.

Estradiol attenuates inflammation and modulates the immune response [25]. Previous studies revealed that estradiol causes inhibition of lipopolysaccharide (LPS) mediated interleukin (IL)-6 secretions in uterine epithelial cells [21,26]. Estradiol and progesterone both inhibit LPS-mediated prostaglandin production in endometrial cells, further highlighting the role of the ovarian steroid hormones in infection sequelae [24].

Mediators of the Innate Immune System Respond to Menstrual Cycle Steroid Hormone Fluctuations

The composition of the genital tract epithelium, the secretion of mucus and the localized immune response follow a similar pattern of hormonal dependence [27-30]. Importantly, there appears to be a relationship between innate immune mediators and endogenous stress response proteins in the development of pelvic inflammation [31].

Human uterine epithelial cells express Toll-like receptors (TLR) 1-9 [32,33]. TLRs interact with specific PAMPs, and receptor binding results in the up-regulation of a pro-inflammatory cytokine cascade and cellular activation [34,35]. Cell surface TLRs (TLR 1,2,4,5,6) recognize microbial products and endogenous ligands while intracellular TLRs (TLR3,7,8,9) recognize nucleic acids [36,37] (Table 1). Therefore, inflammation can be initiated under infectious and non-infectious conditions via TLR activation. Pro-inflammatory cytokines and chemokines are expressed in response to TLR ligand binding in quantitatively and temporally specific patterns [38,39]. Many of these chemical mediators are tightly regulated throughout the menstrual cycle, therefore, changes in secretion induced by TLR activation may well impact on endometrial function in susceptible women [32]. Despite varying patterns of expression for individual immune mediators throughout the menstrual cycle, the cycle-specific changes in immune mediator expression capitulates in the endometrium during the late secretory to early proliferative phase of the cycle [40,41].

There are distinct cell and site-specific differences in TLR expression throughout the female reproductive tract [42]. TLR-2 and TLR-4 are predominantly expressed in the female upper reproductive tract, but rarely in the lower reproductive tract [43-45]. In contrast to all other epithelia, TLR-4 is expressed at much higher levels than TLR-3 within the endometrium possibly due to redundancy between TLR-3, TLR-4 and dsRNA binding proteins [38,46].
Recently, TLR-4 activation by commensal Gram-negative genital tract bacteria (E. coli, Veillonella parvula and Neisseria mucosa) was shown to inhibit human immunodeficiency virus (HIV)-1 macrophage infection in vitro [47]. In contrast, TLR-2 activation by Gram-positive bacteria including lactobacilli enhanced HIV-1 infection of macrophages. The capacity for commensal bacteria to alter the immune response to a potential pathogen via PAMP recognition by TLRs highlights the potential impact of dysbiosis within the commensal microbiota on reproductive health outcomes.

TLRs can also be activated by endogenous ligands (damage associated molecular patterns, DAMPs), which are released from damaged cells during tissue inflammation and injury [48]. Hyaluronic acid and biglycan bind to, and activate, TLR-2 and/or TLR-4 and heparin sulphate, fibrinogen, fibronectin [48]. Heat shock proteins activate TLR-4 [48,49]. Fibronectin is released by endometrial cells in response to progesterone [50]. The activated TLRs then activate macrophages to produce inflammatory chemokines and cytokines [33]. Activation of TLR-2 and TLR-4 by microbial pathogens activates pathways involved in inflammation, tissue repair and adaptive immunity, whilst endogenous ligands binding TLRs -2 and -4 induce inflammation and tissue repair processes [48]. It is proposed that chronic inflammation, which leads to elevated levels of endogenous TLR ligands causes an accumulation of DAMPs thereby lowering the threshold of cellular responsiveness to PAMPs [51]. The net result of which is likely to be ongoing, acute inflammation.

Some bacteria (E. coli, Streptococcus sp., Pasteurella sp., Neisseria meningitidis) avoid the host immune response through molecular mimicry of host glycan structures (heparan sulphate, hyaluronic acid, biglycan) or by altering the cell surface domains releasing charged moieties, which then bind the secreted endogenous antimicrobials such as defensins and lysozyme to neutralize the innate host response. Bacterial species including Streptococcus agalactiae, Neisseria sp. Pseudomonas aeruginosa and Haemophilus sp. appear to promote the cell surface expression of specific glycans and sialic acids in a commensal role to avoid activating the innate immune response [52-55].

Secretory immunoglobulin levels also fluctuate throughout the menstrual cycle in response to the steroid hormones. Secretion is highest during the secretory phase of the cycle, significantly reduced during the proliferative phase and even further reduced at the time of menstruation [56].

The endogenous antimicrobials in the female upper genital tract are capable of inducing cell proliferation, chemotaxis and cytokine secretion. Secretory antimicrobials from the upper genital tract tissues demonstrate selective toxicity against sexually transmitted pathogens, when tested against lower genital tract pathogens and the commensal

---

**Table 1:** Toll-like receptor ligands.

| Toll-like receptor | Endogenous ligands | Exogenous ligands | Cell localization | Genital tract expression |
|--------------------|--------------------|------------------|------------------|--------------------------|
| 1                  | Lipopeptides       | LPS              | Cell surface     | Decidual cells           |
|                    | Modulin            |                  |                  | Endometrial epithelial cells |
| 2                  | Biglycan           | Lipopolysaccharide (LPS) |                  | Cell surface |
|                    | Endoplasmin        | Lipoproteins     |                  |                         |
|                    | Hsp60              | Lipoproteins     |                  |                         |
|                    | Hyaluronan         | Lipotechoic acid (LTA) |                  |                         |
|                    | Monosodium urate crystals | Mannuronic acid polymers | | |
|                    | Veriscan           | Zymosan          |                  |                         |
| 3                  | mRNA               | Viral ssDNA      | Intracellular    |                         |
| 4                  | Biglycan           | Mannuronic acid polymers |                  | Natural killer cells |
|                    | CD138              |                  |                  |                         |
|                    | Endoplasmin        |                  |                  |                         |
|                    | Fibrinogen         |                  |                  |                         |
|                    | Fibronectin        |                  |                  |                         |
|                    | Heparan sulphate   |                  |                  |                         |
|                    | HMGB1              |                  |                  |                         |
|                    | HSP22              |                  |                  |                         |
|                    | Hsp60              |                  |                  |                         |
|                    | Hsp70              |                  |                  |                         |
|                    | HSP70              |                  |                  |                         |
|                    | HSP72              |                  |                  |                         |
|                    | Hyaluronan         |                  |                  |                         |
|                    | Monosodium urate crystals | Mannuronic acid polymers | | |
|                    | Oxpapc             |                  |                  |                         |
|                    | Resistin           |                  |                  |                         |
|                    | Surfactant protein A |                  |                  |                         |
|                    | α-crystallin A chain |                  |                  |                         |
|                    | β-defensin 2       |                  |                  |                         |
| 5                  | Flagellin          |                  | Cell surface     |                         |
| 6                  | Veriscan           | Lipoprotein      | Cell surface     |                         |
|                    | Modulin            |                  |                  |                         |
| 7                  | RNA                | Viral ssRNA      | Intracellular    |                         |
|                    | Small interfering RNA (siRNA) | Viral ssRNA | | |
| 8                  | Human cardiac myosin | Viral ssRNA      | Intracellular    |                         |
|                    | siRNA              |                  |                  |                         |
| 9                  | DNA                | Unmethylated CpG-DNA | Intracellular | |
organism Lactobacillus crispatus [57]. It has been postulated that the microbial cell wall and cell membrane composition may be the reason for differential activity against pathogens [58]. The ovarian steroid hormones produce differential effects on the expression levels of endogenous antimicrobials between the upper and the lower genital tract sites [26,59]. The role of immune response or surveillance in the presence of an endometrial-specific endogenous microbiota has not yet been explored. The upper and lower genital tract sites function in a coordinated but separate fashion, highlighting the need to further investigate the role of the upper genital tract microbiota in susceptibility to infection [60].

**Menstrual phase**

Menstruation involves a breach in the epithelial lining, which may elicit an up-regulation of immune mediators to prevent infection [61-63]. Decreases in estradiol and progesterone levels correlate with changes in the genital tract microbiota. Many antimicrobial peptides including human beta defensins (HBD), elfalin and secretory leukocyte protease inhibitor (SPLI) are over expressed in the peri-menstrual epithelium [4]. Elfalin is also expressed during menstruation [63]. HBD2 levels peak during the menstrual phase of the cycle [59,64].

**Proliferative phase**

Elevated estradiol levels during the proliferative phase of the menstrual cycle result in suppression of innate immunity and the resultant secretion of endogenous antimicrobials. HBD4 levels peak during the proliferative phase of the cycle indicating that there is some level of innate immune response at this stage [65]. However, whilst HBD4 is chemotactic for monocytes, it has no effect on neutrophils or eosinophils [66]. This may provide some insight into the increased diagnosis of genital tract infection during the proliferative phase of the menstrual cycle.

**Secretory phase**

Several innate antimicrobials including HBD and SLPI are also maximally expressed during the secretory phase of the cycle [67,68]. HBD1, 2, 3 and 5 levels and SLPI levels peak during the second half of the menstrual cycle [59,64]. TLR-2-6, and 9 are expressed at maximum levels during this same phase. TLR-4 expression is increased during the secretory phase, which is consistent with its increased expression in response to progesterone [61,62,69,70].

Several innate immune mediators, known to exhibit steroid hormone dependent expression, peak during the period from ovulation to implantation, but have the capacity to deviate from the traditional antigenic response in order to induce immune tolerance, indicating their role in maintaining an adequate endometrial environment for initiating pregnancy [71]. Wira et al. [60] identified the ‘window of vulnerability’ during the 7-10 days post ovulation, where there is increased susceptibility to viral (and possibly bacterial) infection as a result of increased steroid hormone expression leading to decreased innate, humoral and cell mediated immune activity [60].

**Steroid hormones regulate cytokine and chemokine secretion throughout the menstrual cycle**

Chemokine and cytokine production and secretion is also regulated by the ovarian steroid hormones [72]. These inflammatory mediators are constitutively secreted by the epithelial cells within the uterus [42]. Together, the chemokines and cytokines create an environment with a resident immune cell population that contributes to both the inflammation and repair associated with the menstrual cycle and innate immune surveillance [5,73,74]. Seven cytokines and chemokines are constitutively expressed within the genital tract epithelium throughout the menstrual cycle (IL-6, (tumour necrosis factor (TNF)-α, (granulocyte colony stimulating factor (G-CSF), granulocyte macrophage colony stimulating factor (GM-CSF), macrophage migration inhibitory factor (MIF), IL-8, monocyte chemo-attractant protein (MCP)-1 and macrophage inflammatory protein (MIP)-1 β [75]). The TNF system is known to be regulated by steroid hormones, supporting a key role for the family in uterine function [76]. What remains to be elucidated is whether there are distinct differences between the pro-inflammatory cytokine profile required for endometrial remodelling throughout the menstrual cycle, and pathogen initiated cytokine expression [71,77].

**Inflammatory Cell Function During the Menstrual Cycle: Steroid Hormones as Inflammatory Regulators of Myeloid Cells**

Inflammatory cells of the immune system express estrogen, progesterone and androgen receptors, therefore the functional role and spatial distribution of these cells also appears to be menstrual cycle dependent [78] (Figure 2).

Neutrophils express estrogen but not progesterone receptors [79,80]. Both stimulatory and inhibitory effects of estrogen and progesterone on neutrophil release of reactive oxygen species (ROS) have been reported [81-84]. Neutrophil numbers are relatively constant throughout the menstrual cycle, but peak during menstruation following steroid hormone withdrawal and IL-8 up-regulation [85]. Neutrophils are the major responders to infection via TLR activation. Neutrophils phagocytose pathogens, produce oxidation compounds, secrete microbicides and secrete chemokines for cell recruitment in adaptive immunity [6]. Neutrophils also activate prostaglandins and leukotrienes via catalysis of arachidonic acid derived from bacterial cell membranes. Within the tissues, the neutrophils initiate wound healing and repair by promoting angiogenesis and neutrophil extracellular trap formation [86,87].

Progesterone stimulates the production of ROS in monocytes [88]. Progesterone also promotes TNF-α, IL-1β and IL-8 secretion in LPS challenged cells [89,90]. Estradiol, progesterone and androgens reduce the secretion of IL-6 in LPS challenged cells [90]. Estradiol and progesterone also cause reduced secretion of IL-1α and IL-1β [91]. Androgen exposure results in reduced production of prostaglandin E2 [92]. Estradiol reduces IL-8 secretion and inhibits chemotaxis of monocytes to the monocyte chemotactic protein-1 (MCP-1) [93]. The steroid hormones influence the cytokine profile and apoptotic pathways in monocytes.

Macrophages accumulate in the endometrial tissue in the premenstrual period when levels of both estradiol and progesterone decrease, and levels of macrophage chemo-attractants are up-regulated [15,94,95]. Estradiol has been shown to suppress the production of TNF-α, IL-1β and MIP-2, while progesterone stimulates these same factors [96]. Estradiol also appears to block LPS induction of TLR-4 [97]. TLR-4 expression is increased during the secretory phase of the menstrual cycle when progesterone levels peak, and estradiol levels are low. The macrophage phenotype (pro-inflammatory or anti-inflammatory) appears to be induced by TLR signalling in response to either exogenous or endogenous ligands [98].

Eosinophils express estrogen receptors. Estrogen treatment enhances eosinophil adhesion and degranulation of cells [99,100].
Eosinophils do not express progesterone receptors [80]. There is little known about the effects of steroid hormones on basophils, however treatment of cells with immunoglobulin (Ig) E results in enhanced histamine secretion [101]. Estradiol stimulates mast cell degranulation and histamine secretion [102,103]. In contrast, progesterone inhibits mast cell proliferation but stimulates histamine secretion and platelet aggregation factor [104-106]. Platelet aggregation is inhibited by both estradiol and progesterone [107].

The uterine natural killer (NK) cells are low in number during the early proliferative phase of the menstrual cycle, increasing in number until the late secretory phase. The uterine NK cells express TLR-2, TLR-3 and TLR-4, however the cellular response to activation is dependent upon interactions between the multiple endometrial cell populations [98].

The steroid hormone dependent expression of myeloid cells throughout the menstrual cycle is responsible for the simultaneous controlled endometrial tissue degradation, remodelling and repair, and the ability of the epithelium to recognize and respond to microbial pathogens. (See Table 2 for a summary of immune mediator expression throughout the menstrual cycle)

**Dysregulation of Inflammation in Menorrhagia and Dysmenorrhea**

Women with dysfunctional menstrual cycles exhibit alterations in steroid hormone levels, and inflammatory mediators such as prostaglandins, chemokines and cytokines (Table 2). The systemic estradiol levels in women with dysmenorrhea are higher in the late proliferative phase of the cycle when compared to normal cycling women [108].

Genes encoding the pro-inflammatory cytokines IL-1β, IL-6 and TNF were up-regulated during the menstrual and secretory phases of the cycle in dysmenorrheic women whilst members of the TGF-β superfamily were down-regulated in these women when compared to women with pain-free menstrual cycles [109]. The authors concluded that the anti-inflammatory response was insufficient to dampen the pro-inflammatory cascade. There was an increased level of expression of growth factors during the menstrual phase of the cycle, which decreased during the proliferative and secretory phases [109]. The down-regulation of TGF-β super family members and the corresponding up-regulation of pro-inflammatory cytokines results in prostaglandin release, induction of additional inflammatory mediators, hypoxic ischemia within the uterus and pain.

Prostaglandin synthesis and the number of prostaglandin receptors are increased in uterine tissues in women with menorrhagia compared to women with normal menstrual loss, and levels correlate with menstrual loss [12]. Prostaglandin concentrations are also higher in the menstrual blood collected from women with dysmenorrhea compared to women without menstrual pain.

It is possible that the altered expression of pro-inflammatory mediators within the endometrial epithelium of women with dysfunctional menstrual bleeding may lead to alterations in the cellular responses necessary for maintaining homeostasis or responding to pathogen challenge. Constant activation of TLRs during prolonged bleeding, inflammation and repair may reduce the threshold for TLR activation by exogenous ligands leading to hyper-responsiveness to PAMP recognition leading to ongoing inflammation and pathology.

![Figure 2: Genital tract commensals and pathogens fluctuate throughout the menstrual cycle.](image-url)
| Mediator | Normal menstrual cycle | Menorrhagia | Dysmenorrhea | References |
|----------|------------------------|-------------|--------------|------------|
| **Cytokines/chemokines** | | | | |
| GMCSF | Regulator and activator of granulocytes and macrophages | | | [183] |
| Gro-α | Neutrophil chemotaxis | | | [184] |
| **IL-1** | Ovulation promotion | | | |
| | Induces IL-6 production for angiogenesis | | | [185,186] |
| | Enhances IL-8 production | | | [187,188] |
| | Inhibited by progesterone | | | |
| | Inhibited by estradiol | | | |
| | Induces NO production | | | |
| **IL-1α** | Stimulates T and B lymphocyte proliferation | | | [189] |
| | Stimulates prostaglandin production | | | |
| **IL-1β** | Endometrial inflammation at menses | | | [190] |
| | Inhibits apoptosis by NO production | | | |
| | Stimulates T and B lymphocyte proliferation | | | |
| | Stimulates prostaglandin production | | | |
| **IL-1ra** | Antagonises IL-1 to prevent tissue damage after ovulation | | | [191] |
| **IL-2** | Progesterone stimulation | | | [192] |
| | HCG suppression | | | |
| **IL-6** | Role in steroid hormone production | | Elevated at menstruation | [188,193,194] |
| | Reduces granulosa cell proliferation | | | |
| | Inhibited by estradiol | | | |
| **IL-8** | Up-regulated by progesterone withdrawal | | | [72,94,195] |
| | Chemotaxis and activation of monocytes and neutrophils | | | |
| | Proliferation | | | |
| | Menstruation | | | |
| | Angiogenesis | | | |
| | Prevention of infection | | | |
| | Prevention of tissue damage after ovulation | | | |
| **IL-10** | Inhibition of progesterone production | | | [196] |
| | Anti-inflammatory antagonist to IL-1, IL-2, IL-6, TNF α | | | |
| **LIF** | Estradiol biosynthesis | | | [193] |
| **MCP-1** | Up-regulated by progesterone withdrawal | | | [72,94,195] |
| | Chemotaxis and activation of monocytes and neutrophils | | | |
| | Proliferation | | | |
| | Angiogenesis | | | |
| | Menstruation | | | |
| **RANTES** | Androgen production and induction of LH receptors | | | [197] |
| | Inhibited by estradiol | | | |
| **TGF β** | Endometrial inflammation at menses | | Down regulated at menstruation | [109] |
| | Androgen production | | | |
| | Induction of LH receptors | | | |
| | Inhibited by estradiol | | | |
| **TNF α** | Endometrial inflammation at menses | | Increased at menstruation | [109,188,197] |
| | Androgen production | | | |
| | Induction of LH receptors | | | |
| | Inhibited by estradiol | | | |

**Growth factors**

| Mediator | Normal menstrual cycle | Menorrhagia | Dysmenorrhea | References |
|----------|------------------------|-------------|--------------|------------|
| **EGF** | Up-regulated with estradiol | | | [198] |
| | Endometrial proliferation | | | |
| **FGF** | Endometrial maturation and regeneration | Decreased receptor expression | | [199,200] |
| | Elevated during proliferative and secretory phases | | | |
| **VEGF** | Angiogenesis | Increased proliferative activity | | [199] |

**Prostaglandins**

| Mediator | Normal menstrual cycle | Menorrhagia | Dysmenorrhea | References |
|----------|------------------------|-------------|--------------|------------|
| **COX-2** | Activated by progesterone withdrawal | Elevated during menstruation | | [201,202] |
| | Prostaglandin activation resulting in leukocyte influx | | | |
| | Endometrial breakdown | | | |
| **PGE** | Angiogenesis | Elevated at menstruation | | [199,201,203] |
| | Elevated at menstruation | | | |
| **PGF2α** | Up-regulated following progesterone withdrawal | Elevated in secretory phase | | [195,203-205] |
| | Inflammation at menstruation | | | |
| **TXA2** | Vasocostriction of spiral arterioles inducing hypoxia | Elevated at menstruation | | | |
| | Stimulates smooth muscle contraction for endometrial sloughing | | | |
| | Menstrual pain nociception | | | |

**Matrix metalloproteases**

| Mediator | Normal menstrual cycle | Menorrhagia | Dysmenorrhea | References |
|----------|------------------------|-------------|--------------|------------|
| **MMP-2** | Relaxation of endometrial blood vessels enhancing edema | Reduced at menstruation | | [206] |
| | and leukocyte recruitment | | | |
| **MMP-9** | Menstrual pain nociception | Reduced at menstruation | | [206] |

Table 2: Cytokine/chemokine/prostaglandin expression in endometrium in normal and in pathology.
Infection Risk and Commensal Microbes

The menstrual cycling of the endometrium represents a constant tissue remodelling process encompassing cell death, proliferation and migration. The endometrium is one of very few tissues that can undergo such significant remodelling without scar tissue formation, further supporting the tight regulation surrounding inflammation during this process [110]. The commensal microbiota is responsible for maintaining epithelial homeostasis and integrity, and contributes to the tissue damage response via recognition by innate immune cells expressing TLRs [111-113].

There exists a close relationship between regulated microbial growth in the female genital tract and the menstrual cycle. Genital tract infections occur in a menstrual cycle-dependent fashion, which can be attributed to changes in secreted levels of the steroid hormones estradiol and progesterone, which influence the expression of immune mediators [30,61,114]. Many members of the endogenous microbiota use these hormones as growth factors, while for others they are inhibitory [115]. The concentration of opportunistic pathogens increases during menstruation and the early proliferative phase of the cycle at the time of progesterone withdrawal. Levels of the endogenous lactobacilli peak with estradiol levels during the secretory phase of the cycle [116].

Previous studies indicate that there are some changes in Lactobacillus sp. community composition, but that L. crispatus is associated with long-term stability within the vaginal microbiome [117]. However, absence of Lactobacillus sp. has been reported in healthy, asymptomatic women with a lower genital tract microbiota dominated by other lactic acid producing species including Atopobium sp., Megasphaera sp. or Leptotrichia sp. [118,119]. These reports may suggest that maintenance of the host microbiome (expression of microbial genes and subsequent secretion of metabolites) rather than the host endogenous microbiota (individual microbial species) is key in preserving a healthy genital tract environment. The inability to identify a site-specific (vaginal) ‘core microbiome’ in the healthy asymptomatic women of reproductive age supports the concept of functional redundancy in the microbiome [120-123]. Whilst functional redundancy may imply overall equilibrium in the system, it is reasonable to assume that the relative abundance of some members of the commensal microbial community will activate the innate immune response to a greater extent than for example the non-antigenic endogenous lactobacilli, leading to activation of a pro-inflammatory cascade, dysbiosis and instability within the specific microbiome. Functional redundancy has also been reported for the human microbiome in healthy individuals and in the gut microbiome in lean and obese individuals [124,125].

Microbial pathogens have at their disposal diverse mechanisms for interacting with and manipulating host cells for the benefit of their survival [126]. Bacteria are capable of selectively inducing either pro-apoptotic or anti-apoptotic pathways in human cells to mediate their survival within the host environment [127]. Apoptosis plays a key role in microbial pathogenesis and antibacterial immunity [128]. The recognition of apoptotic cells by the immune system leads to phagocytosis and activation of anti-inflammatory mediators [129]. However, for intracellular pathogens, survival is dependent on inhibition of apoptosis of the host cell [130]. The endogenous genital tract Lactobacillus sp. are capable of inducing this switching independently of pH and lactate, further supporting a role for the microbiome in reproductive pathology or homeostasis [131-133].

Numbers of anaerobic Gram-positive cocci increase during the menstrual phase of the cycle, and in response to antibiotic administration [134]. An increase in the presence of the Gram-positive cocci including Streptococcus anginosus, Peptostreptococcus anaerobius and P. asaccharolyticus has been linked to disturbances in the lower genital tract microbiota. Interestingly, these species appear to exist in equilibrium with the lactobacilli in healthy women, but can be disrupted in susceptible women during the menstrual phase of the cycle. The complexity of the host-microbe interaction is further highlighted by the inability to achieve resolution of all dysbioses following antibiotic treatment [135]. Treatment resistance of Gardnerella vaginalis in confirmed cases of bacterial vaginosis further highlights the need to consider the microbiome in toto, rather than only an individual member of the genital tract microbiota when treating genital tract dysbiosis [136-138]. Further, abnormalities in the lower genital tract microbiota are implicated in endometrial pathology including adverse obstetric outcomes [139-141].

Evidence of transient exposure to microbial commensals or pathogens has been reported in the upper genital tract [142-145]. Microorganisms have been isolated from the endometrial cavity in both the presence and the absence of symptoms of infection and/or inflammation, suggesting that the presence of microorganisms within the upper genital tract may not always reflect a pathological process; rather the endometrial cavity is not sterile, and harbours an endogenous microbiota [146-150]. Cultures of vaginal and endocervical specimens have proven to be poor indicators of the presence of microorganisms within the endometrial cavity and discordant results for microbial species were obtained when sampling both sites in asymptomatic women [151,152]. In susceptible women, the endogenous endometrial microbiota may lead to endometrial pathology or may serve to maintain homeostasis.

Nutritional Requirements of the Host Microbiota

A critical factor controlling the composition and distribution of the host microbiota is the nutritional requirements of individual microbial community members. Members of the commensal microbiota implement an array of direct interaction strategies to compete with opportunistic pathogens present as minority community members. Commensals produce bacteriocins and toxins that inhibit members of the same or closely related species [153]. Members of the endogenous microbiota are also capable of altering the host environment by shifting the pH creating a niche prohibitive to pathogen growth [153-155]. The consumption of nutrients and production of metabolites by endogenous microbiota can also alter pathogen growth and virulence [156,157]. However, some pathogens (including members of the Enterobacteriaceae and obligate anaerobes) have evolved to use alternative nutrients to manage nutritional competition by commensals [158,159]. Alterations of host inflammation in response to pathogens can impede the growth of some community members including obligate anaerobes from the families Bacteroidetes and Firmicutes more rapidly than others (E. coli) due to their inability to utilize electron acceptors such as nitrate, which is generated by an inflamed epithelium [160]. There are also opportunistic pathogens capable of using resources more efficiently than commensals. Iron, an essential resource for bacterial growth is utilized by iron-chelating siderophore producing bacteria. Host cells can actively block siderophore production and cellular proliferation in members of the endogenous microbiota making competition with opportunists difficult [161]. Hemoglobin is a precursor of many natural antimicrobial peptides [162]. Erythrocytes from the endometrium may therefore be another source of antimicrobial activity acting alongside epithelial cells and leukocytes [163]. Hemoglobin derived peptides exhibit diverse activities including immunomodulatory action [164]. In
Contrast, hemoglobin can also promote microbial growth by providing iron or interfering with oxygen metabolism by leukocytes. Hemocidins (short chain alpha-hemoglobins) demonstrate antimicrobial activity against bacteria, particularly Gram-negative species. Hemocidins have been isolated from post cesarean section uterine lochia [162,165].

Menorrhagia is characterized by excessive menstrual blood loss, whilst dysmenorrhea is associated with increased inflammation and cell damage. Therefore, in these women, the haemoglobin concentration is likely to exceed that of other endogenous antimicrobial peptides within the uterine cavity. Notably, despite producing an excessive amount of bacterial nutrition (in the form of menstrual blood), menorrhagia has not been associated with an increased incidence of pelvic infection. The endogenous Lactobacillus sp. do not require iron for their growth, suggesting that their numbers are not likely to increase significantly during menstruation in contrast to many opportunistic members of the endogenous microbiota (including G. vaginalis) who have developed multiple systems to exploit both low level and excess free iron [166,167]. It is therefore possible that for women with dysfunctional menstrual bleeding there exists a delicate balance between increased numbers of iron-dependent pathogens, and increased levels of antimicrobial hemocidins. A robust endogenous microbiota, such as that linked with localized administration of exogenous progesterone is more likely to tolerate fluctuations in individual species numbers and nutrient supply. It seems reasonable to assume that in these women, the immune system must choose between maintaining homeostasis and mounting an immune response to pathogen challenge.

Microbes and their Interaction with Immune Regulators

Staphylococcus aureus and microbial products signalling via TLR-
2 and TLR-5 induce epithelial repair, survival and growth [168]. This repair occurs via an independent non-inflammatory pathway linking TLR activation and epidermal growth factor receptors associated with epithelial cells [168]. Peptidoglycan has been associated with wound closure and repair via epithelial cell proliferation and migration. TLR-2 and TLR-5 ligands (peptidoglycan, lipotechoic acid and flagellin) all appear capable of promoting wound repair. It is well accepted that TLR activation causes pro-inflammatory cytokine (IL-1β, TNF-α, IL-6 and IL-8) release by epithelial cells, however TLR mediated epithelial repair appears independent of pro-inflammatory cytokine induced cellular migration and proliferation at the wound site. This data suggests that the endogenous microbiota is capable of enhancing tissue remodelling and repair.

Whilst TLRs are powerful and somewhat specific immune regulators, recent evidence suggests that activation of both TRL-2 and TLR-6 is required for an adequate innate response to Mycoplasma sp. infection [169]. Distinct TLRs have the potential to mediate epithelial homeostasis in favour of ongoing pathology or regeneration and repair. Many bacteria, particularly anaerobic species, which are common inhabitants of the endogenous genital tract microbiota produce large quantities of short chain fatty acids (acetic, butyric and propionic acid). Short chain fatty acids are capable of modulating the immune response by inhibiting the production of pro-inflammatory cytokines, chemotaxis and phagocytosis [170-172]. The metabolites also cause apoptosis in neutrophils [173,174]. Commensal bacteria reported to be opportunistic pathogens demonstrate the capacity to alter the immune response as a trade-off for virulence. Highly invasive strains of Prevotella bivia produced the weakest pro-inflammatory (IL-6 and IL-8) response during in vitro culture when compared to non-invasive strains [175].

Lactobacillus iners, a common genital tract commensal is capable of up-regulating constitutive SLPI secretion, however, increased levels of L. iners results in the reverse effect [176]. Interestingly, L. iners is the Lactobacillus sp. frequently associated with intermediate or bacterial vaginosis vaginal flora and is the dominant vaginal taxon reported after treatment for bacterial vaginosis [177-181]. L. crispatus causes a strong reduction in SLPI secretion, and presence of this Lactobacillus sp. is associated with an absence of bacterial vaginosis [181]. Current evidence suggests that the dominant genital tract lactobacilli can contribute to the mucosal immune response in diverse ways. The regulatory effect of SLPI secretion is inversely associated with the capacity of the invading or commensal bacteria to evoke a pro-inflammatory response. It is therefore possible that microbes present in the genital tract are capable of causing down-regulation of the immune response in exchange for reduced virulence [182].

Microbial pathogens and their products appear to have two possible roles in epithelia: Cell death, injury and inflammation, or tissue repair, cell migration and proliferation, and limited inflammation. Therefore, under physiological conditions, the presence of certain members of the endometrial microbiota may control epithelial barrier integrity without causing inflammation (Figure 3).

Conclusion

Subacute inflammation associated with dysbiosis in the endogenous endometrial microbiota in women with primary menorrhagia and/or dysmenorrhoea may cause TLR binding, and subsequent activation of the pro-inflammatory cascade leading to increased secretion of mediators involved in apoptosis, haemostasis, inflammation and repair. Alterations in progestagen and cytokine expression in the endometrium of these women, combined with an altered microbiome may well contribute to ongoing activation of an innate immune response leading to dysregulation of the normal menstrual cycle associated with tissue remodelling. The menstrual phase of the cycle is frequently associated with an increased notification of genital tract infection possibly due to heightened immune surveillance, or a reduced response threshold due to persistent TLR activation by DAMPs. Subsequent increases in cellular damage and the release of free iron and hemocidins within this niche may lead to dysbiosis of the endometrial microbiome and may explain why some women do not respond to treatment. Characterization of the endometrial microbiome in women with normal menstrual cycles and in those with dysfunctional menstrual bleeding may elucidate redundancy within the microbiome and identify targets for restoring eubiosis.

References
1. Sales KJ, Jabbour HN (2003) Cyclooxygenase enzymes and prostaglandins in pathology of the endometrium. Reproduction 126: 559-567.
2. Rees MC, Turnbull AC (1989) Menstrual disorders—an overview. Baillieres Clin Obstet Gynaecol 3: 217-226.
3. Duckitt K (2007) Medical management of perimenopausal menorrhagia: an evidence-based approach. Menopause Int 13: 14-18.
4. King AE, Critchley HO (2010) Oestrogen and progesterone regulation of inflammatory processes in the human endometrium. J Steroid Biochem Mol Biol 120: 116-128.
5. Critchley HO, Kelly RW, Brenner RM, Baird DT (2001) The endocrinology of menstruation—a role for the immune system. Clin Endocrinol (Oxf) 55: 701-710.
6. Wira CR, Fahey JV, Sentman CL, Plioi PA, Shen L (2005) Innate and adaptive immunity in female genital tract: Cellular responses and interactions. Immunol Rev 206: 306-335.
7. Lessey BA, Killam AP, Metzger DA, Haney AF, Greene GL, et al. (1988) Immunohistochemical analysis of human uterine estrogen and progesterone receptors throughout the menstrual cycle. J Clin Endocrinol Metab 67: 334-340.
8. Critchley HO, Brenner RM, Henderson TA, Williams K, Nayan NR, et al. (2001) Estrogen receptor beta, but not estrogen receptor alpha, is present in the vascular endothelium of the human and nonhuman primate endometrium. J Clin Endocrinol Metab 86: 1370-1378.
9. Mote PA, Balleine RL, McGowan EM, Clarke CL (1999) Co-localization of progesterone receptors A and B by dual immunofluorescent histochemistry in human endometrium during the menstrual cycle. J Clin Endocrinol Metab 84: 2963-2971.
10. Mote PA, Balleine RL, McGowan EM, Clarke CL (2000) Heterogeneity of progesterone receptors A and B expression in human endometrial glands and stroma. Hum Reprod 15 Suppl 3: 48-56.
11. Mertens HJ, Heineman MJ, Theunissen PH, de Jong FH, Evers JL (2001) Androgen, estrogen and progesterone receptor expression in the human uterus during the menstrual cycle. Eur J Obstet Gynecol Reprod Biol 90: 58-65.
12. Jabbour HN, Sales KJ (2004) Prostaglandin receptor signalling and function in human endometrial pathology. Trends Endocrinol Metab 15: 398-404.
13. Baird DT, Cameron ST, Critchley HO, Drudy TA, Howe A, et al. (1996) Prostaglandins and menstruation. Eur J Obstet Gynecol Reprod Biol 70: 15-17.
14. Miura S, Kusumoto K, Kitaiki M, Hiraki K, Moriyama S, et al. (2006) Differential infiltration of macrophages and progestagen production by different uterine leiomyomas. Hum Reprod 21: 2545-2554.
15. Jones RL, Kelly RW, Critchley HO (1997) Chemokine and cyclooxygenase-2 expression in human endometrium coincides with leukocyte accumulation. Hum Reprod 12: 1300-1306.
16. Jabbour HN, Kelly RW, Fraser HM, Critchley HO (2006) Endocrine regulation of menstruation. Endocr Rev 27: 17-46.
17. Hofmann GE, Scott RT Jr, Bergh PA, Deligdisch L (1991) Immunohistochemical localization of epidermal growth factor in human endometrium, decidua and placenta. J Clin Endocrinol Metab 73: 882-887.
18. Zhou J, Duspin BA, Giudice LC, Bondy CA (1994) Insulin-like growth factor system gene expression in human endometrium during the menstrual cycle. J Clin Endocrinol Metab 79: 1723-1734.

19. Gurgide E, Gusberg SB, Tseng L (1976) Estradiol binding and metabolism in human endometrial hyperplasia and adenocarcinoma. J Steroid Biochem 7: 891-896.

20. Falany CJ, Falany CN (1996) Regulation of estrogen sulfotransferase in human endometrial adenocarcinoma cells by progesterone. Endocrinology 137: 1395-1401.

21. Wira CR, Fahey JV, Ghosh M, Patel MV, Hickey DK, et al. (2010) Sex hormone regulation of innate immunity in the female reproductive tract: The role of epithelial cells in balancing reproductive potential with protection against sexually transmitted pathogens. American Journal of Reproductive Immunology 63:544-565.

22. Nikolaeaich KN, Ivanovich SJ, Victorovich SS (1991) Major reproduction hormones as regulators of cell-to-cell interactions in humoral immune responses. Brain Behav Immun 5: 149-161.

23. Beagley KW, Gockel CM (2003) Regulation of innate and adaptive immunity by the female sex hormones oestradiol and progesterone. FEBS Immunol Med Microbiol 38: 13-22.

24. Herath S, Fischer DP, Werling D, Williams EJ, Lilly ST, et al. (2006) Expression and function of Toll-like receptor 4 in the endometrial cells of the uterus. Endocrinology 147: 562-570.

25. Merkel SM, Alexander S, Zufall E, Oliver JD, Huet-Hudson YM (2001) Essential role for estrogen in protection against Vibrio vulnificus-induced endotoxic shock. Infect Immun 69: 6119-6122.

26. Fahey JV, Wright JA, Shen L, Smith JM, Ghosh M, et al. (2008) Estradiol selectively regulates innate immune function by polarized human uterine epithelial cells in culture. Mucosal Immunol 1: 317-325.

27. Brabin L1 (2001) Hormonal markers of susceptibility to sexually transmitted infections: Are we taking them seriously? BMJ 323: 394-395.

28. Cerutti M, Canestrelli M, Condemi V, Piamentelli D, De Paolis P, et al. (1994) Methods of contraception and rates of genital infections. Clin Exp Obstet Gynecol 21: 119-123.

29. McGregor JA, French JI, Richter R, Vuchetich M, Bachus V, et al. (1990) Cervicovaginal microflora and pregnancy outcome: Results of a double-blind, placebo-controlled trial of erythromycin treatment. Am J Obstet Gynecol 163: 1580-1591.

30. Sonnex C (1998) Influence of ovarian hormones on urogenital infection. Sex Transm Infect 74: 11-19.

31. Khan KN, Kitajima M, Inoue T, Tateishi S, Fujishita A, et al. (2013) Additive effects of inflammation and stress reaction on Toll-like receptor 4-mediated growth of endometriotic stromal cells. Hum Reprod 28: 2794-2803.

32. Schafer TM, Desouza K, Fahey JV, Beagley KW, Wira CR (2004) Toll-like receptor (TLR) expression and TLR-mediated cytokine/chemokine production by human uterine epithelial cells. Immunology 112: 428-436.

33. Schafer L, Babelova A, Kiss E, Hauser HJ, Balivo M, et al. (2005) The matrix component biglycan is pro-inflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J Clin Invest 115: 2223-2233.

34. Kopp E, Medzhitov R (2003) Recognition of microbial infection by Toll-like receptors. Curr Opin Immunol 15: 396-401.

35. Kawai T, Akira S (2005) Pattern recognition with Toll-like receptors. Curr Opin Immunol 17: 338-344.

36. Medzhitov R (2007) Toll-mediated innate immune recognition. Semin Immunol 19: 1-2.

37. Hacker H, Valubas RM, Takeuchi O, Hoshino K, Akira S, et al. (2000) Immune cell activation by bacterial Cpg-DNA through myeloid differentiation marker 88 and tumor necrosis factor receptor-associated factor (TRAF6). J Exp Med 192: 595-600.

38. Jorgenson RL, Young SL, Lesmeister MJ, Lyddon TD, Misfeldt ML (2005) Human endometrial epithelial cells cyclically express Toll-like receptor 3 (TLR3) and exhibit TLR3-dependent responses to dsRNA. Hum Immunol 66: 489-492.

39. Schafer TM, Fahey JV, Wright JA, Wira CR (2005) Migration inhibitory factor secretion by polarized uterine epithelial cells is enhanced in response to the TLR3 agonist poly (I:C). Am J Reprod Immunol 54: 193-202.

40. Weisberger M, Frits-Moller A, Bremmelgaard A (1994) Infections related to the menstrual cycle. A study of five otherwise healthy women with recurrent abscesses and a review of the literature. Infect Immun 62: 395-400.

41. Wira CR, Fahey JV, White H, Yeaman G, Givan A, et al. (2002) The mucosal immune system in the female reproductive tract: Influence of stage of the menstrual cycle and menopause on mucosal immunity in the uterus. Taylor and Francis, London.

42. Ochiel DO, Fahey JV, Ghosh M, Haddad SN, Wira CR (2008) Innate immunity in the female reproductive tract: Role of sex hormones in regulating uterine epithelial cell protection against pathogens. Curr Womens Health Rev 4: 102-117.

43. Pioli PA, Amiel E, Schaefer TM, Connolly JE, Wira CR, et al. (2004) Differential expression of Toll-like receptors 2 and 4 in tissues of the human female reproductive tract. Infect Immun 72: 5799-5806.

44. Itoh H, Nasu K, Nishida M, Matsumoto H, Yuge A, et al. (2006) Human oviductal stromal fibroblasts, but not oviductal epithelial cells, express Toll-like receptor 4: The site-specific mucosal immunity of the human fallopian tube against bacterial infection. Am J Reprod Immunol 55: 91-101.

45. Fazeli A, Bruce C, Anumba DO (2005) Characterization of Toll-like receptors in the female reproductive tract in humans. Hum Reprod 20: 1372-1378.

46. Althorn S, Böing C, Koch AA, Kinng R, Gashaw I (2008) TLR3 and TLR4 expression in healthy and diseased human endometrium. Reprod Biol Endocrinol 6: 40.

47. Ahmed N, Hayashi T, Hasegawa A, Furukawa H, Okamura N, et al. (2010) Suppression of human immunodeficiency virus type 1 replication in macrophages by commensal bacteria preferentially stimulating Toll-like receptor 4. Journal of General Virology 91: 2804-2813.

48. Iwasaki A, Medzhitov R (2010) Regulation of adaptive immunity in the human immune system. Science 327: 291-295.

49. Khan KN, Kitajima M, Hiraki K, Fujishita A, Sekine I, et al. (2009) Toll-like receptors in innate immunity: Role of bacterial endotoxin and toll-like receptor 4 in endometrium and endometriosis. Gynecol Obstet Invest 68: 40-52.

50. Zhu HH, Huang JR, Mazela J, Eljas T, Jeng L (1992) Progestin stimulates the biosynthesis of fibronectin and accumulation of fibronectin mRNA in human endometrial stromal cells. Hum Reprod 7: 141-146.

51. Erridge C1 (2010) Endogenous ligands of TLR2 and TLR4: Agonists or assistants? J Leukoc Biol 87: 989-999.

52. Ajit V, Cumminga R, Esko J, Freeze H, Stanley P, et al. (2009) Essential of glycobiology. Cold Spring Harbor Laboratory Press, New York.

53. Carlin AF, Uchiyama S, Chang YC, Lewis AL, Nizet V, et al. (2009) Molecular mimicry of host sialylated glycans allows a bacterial pathogen to engage neutrophil Siglec-9 and dampen the innate immune response. Blood 113: 3333-3336.

54. Varki A, Gagneux P (2012) Multifarious roles of sialic acids in immunity. Ann N Y Acad Sci 1253: 16-36.

55. Varki A (2011) Since there are PAMPs and DAMPs, there must be SAMPs? Glycan “self-associated molecular patterns” dampen innate immunity, but pathogens can mimic them. Glycobiology 21: 1121-1124.

56. Sullivan DA, Richardson GS, MacLaughlin DT, Wira CR (1984) Variations in the levels of secretory component in human uterine fluid during the menstrual cycle. J Steroid Biochem 20: 509-513.

57. Wira CR, Ghosh M, Smith JM, Shen L,Connor RI, et al. (2011) Epithelial cell secretions from the human female reproductive tract inhibit sexually transmitted pathogens and Candida albicans but not Lactobacillus. Mucosal Immunol 4: 335-342.

58. Klotman ME, Chang TL (2006) Defensins in innate antiviral immunity. Nat Rev Immunol 6: 447-456.

59. King AE, Fleming DC, Critchley HO, Kelly RW (2003) Differential expression of the natural antimicrobials, beta-defensins 3 and in human endometrium. J Reprod Immunol 59: 1-16.

60. Wira CR, Fahey JV (2008) A new strategy to understand how HIV infects women: Identification of a window of vulnerability during the menstrual cycle. AIDS 22: 1909-1917.

61. Aflatoonian R, Fazeli A (2008) Toll-like receptors in female reproductive tract and their menstrual cycle dependent expression. J Reprod Immunol 77: 7-13.
62. Aftaabonian R, Tuckerman E, Elliott SL, Bruce C, Aftaabonian A, et al. (2007) Menstrual cycle-dependent changes of Toll-like receptors in endometrium. Hum Reprod 22: 586-593.
63. King AE, Critchley HO, Sallenave JM, Kelly RW (2003) Estrogen, neutrophils and the human endometrium: An antiprotease and antimicrobial molecule expressed during menstruation. J Clin Endocrinol Metab 88: 4426-4431.
64. King AE, Critchley HO, Kelly RW (2003) Innate immune defences in the human endometrium. Reprod Biol Endocrinol 1: 116.
65. Wira CR, Patel MV, Ghosh M, Mukura L, Fahey JV (2011) Innate immunity in the female reproductive tract: Endocrine regulation of endogenous antimicrobial protection against HIV and other sexually transmitted infections. Am J Reprod Immunol 65: 198-211.
66. Cnoteo García JR, Krause A, Schulz S, Rodríguez-Jiménez FJ, Klüver E, et al. (2001) Human b-defensin 4: A novel inducible peptide with a specific salt-sensitive spectrum of antimicrobial activity. The FASEB J.
67. Fleming DC, King AE, William AR, Critchley HO, Kelly RW (2003) Hormonal contraception can suppress natural antimicrobial gene transcription in human endometrium. Fertil Steril 79: 856-863.
68. King AE, Critchley HO, Kelly RW (2000) Presence of secretory leukocyte protease inhibitor in human endometrium and first trimester decidua suggests an antibacterial protective role. Mol Hum Reprod 6: 191-196.
69. Hirata T, Osuga Y, Hamasaki K, Hirota Y, Nose É, et al. (2007) Expression of toll-like receptors and 9 genes in the human endometrium during the menstrual cycle. J Reprod Immunol 74: 53-60.
70. Hirata T, Osuga Y, Hirota Y, Koga K, Yoshino O, et al. (2005) Evidence for the presence of toll-like receptor 4 system in the human endometrium. J Clin Endocrinol Metab 90: 548-556.
71. Robertson SA1 (2000) Control of the immunological environment of the uterus. Rev Reprod 5: 164-174.
72. Kayissi UA, Mahutte NG, Arici A (2002) Uterine chemokines in reproductive physiology and pathology. Am J Reprod Immunol 47: 213-221.
73. Yeaman GR, Collins JE, Fanger MW, Wira CR, Lydyard PM (2001) CD8+ T cells in human uterine endometrial lympoid aggregates: Evidence for accumulation of cells by trafficking. Immunology 102: 434-440.
74. Rescigno M, Urbano M, Valzasia B, Franchin M, Rotta G, et al. (2001) Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat Immunol 2: 361-367.
75. Fahey JV, Schafer TM, Channon JY, Wira CR (2005) Secretion of cytokines and chemokines by polarized human epithelial cells from the female reproductive tract. Hum Reprod 20: 1439-1446.
76. Haider S, Knöfler M (2009) Human tumour necrosis factor: Physiological and pathological roles in placenta and endometrium. Placenta 30: 111-123.
77. Quayle AJ (2002) The innate and early immune response to pathogen challenge in the female genital tract and the pivotal role of epithelial cells. J Reprod Immunol 57: 81-79.
78. Gilleron SC (2010) Sex steroids as inflammatory regulators. J Steroid Biochem Mol Biol 120: 105-115.
79. Molero L, García-Duran M, Díaz-Recasens J, Rico L, Casado S, et al. (2002) Expression of estrogen receptor subtypes and neuronal nitric oxide synthase in neutrophils from women and men: Regulation by estrogen. Cardiovasc Res 56: 43-51.
80. Aerts JL, Christiaens MR, Vandekerckhove P (2002) Evaluation of progesterone receptor expression in eosinophils using real-time quantitative PCR. Biochim Biophys Acta 1571: 167-172.
81. Molloy EJ, O'Neill AJ, Grantham JJ, Sheridan-Pereira M, Fitzpatrick JM, et al. (2003) Sex-specific alterations in neutrophil apoptosis: The role of estradiol and progesterone. Blood 102: 2653-2659.
82. Chiang K, Parthasarathy S, Santanam N (2004) Estrogen, neutrophils and oxidation. Life Sci 75: 2425-2438.
83. Bekesi G, Tulassay Z, Raczk F, Feher J, Szekacs B, et al. (2007) The effect of estrogen on superoxide anion generation by human neutrophil granulocytes: possible consequences of the antioxidant defence. Gynecol Endocrinol 23: 451-454.
84. Bekesi G, Kakucs R, Varioin S, Raczk Z, Spritz D, et al. (2000) In vitro effects of different steroid hormones on superoxide anion production of human neutrophil granulocytes. Steroids 65: 899-984.
85. Hickey DK, Patel MV, Fahey JV, Wira CR (2011) Innate and adaptive immunity at mucosal surfaces of the female reproductive tract. Stratification and integration of immune protection against the transmission of sexually transmitted infections. J Reprod Immunol 88: 185-194.
86. Theilgaard-Monch K, Knudsen S, Follin P, Borregaard N (2004) The transcriptional activation program of human neutrophils in skin lesions supports their important role in wound healing. J Immunol 172: 7684-7693.
87. Phillipson M, Kubes P (2011) The neutrophil in vascular inflammation. Nat Med 17: 1381-1390.
88. Martinoi C, Zocchi E, Querzola F, Damiani G, Zaccheo D (1984) Progesterone enhances reactive oxygen intermediates production by cultured human monocytes. Boll Soc Ital Biol Sper 60: 1871-1877.
89. Jain SK, Kannan K, Prouly L, Jain SK (2004) Progesterone, but not 17β-estradiol, increases TNF-alpha secretion in U937 monocytes. Cytochrome 28: 102-105.
90. Peltier MR, Tee SC, Smulian JC (2008) Effect of progesterone on pro-inflammatory cytokine production by monocytes stimulated with pathogen-associated with preterm birth. Am J Reprod Immunol 60: 346-353.
91. Morishita M, Miyagi M, Iwamoto Y (1999) Effects of sex hormones on production of interleukin-1 by human peripheral monocytes. J Periodontol 70: 757-760.
92. Miyagi M, Morishita M, Iwamoto Y (1993) Effects of sex hormones on production of prostaglandin E2 by human peripheral monocytes. J Periodontol 64: 1075-1078.
93. Yamada K, Hayashi T, Kuzuya M, Naito M, Asai K, et al. (1996) Physiological concentration of 17 β-estradiol inhibits chemotaxis of human monocytes in response to monocyte chemotactic protein 1. Artery 22: 24-35.
94. Jones RL, Hannah NJ, Kaitu’u LJ, Zhang J, Salamonsen LA (2004) Identification of chemokines important for leukocyte recruitment to the human endometrium at the times of embryo implantation and menstruation. J Clin Endocrinol Metab 89: 6155-6167.
95. Kamat BR, Isaacson PG (1987) The immunocytochemical distribution of leukocytic subpopulations in human endometrium. Am J Pathol 127: 66-73.
96. Huang EJ, Wu CC, Lee SD, Chen JH, Liu JY, et al. (2006) Opposing action of estrogen receptors alpha and beta on tumor necrosis factor-alpha gene expression and caspase-8-mediated apoptotic effects in H292 cell. Mol Cell Biochem 287: 137-145.
97. Vegeto E, Ghiselli S, Mekos E, Ec S, Beltrame S, et al. (2004) Regulation of the lipopolysaccharide signal transduction pathway by 17 β-estradiol in macrophage cells. J Steroid Biochem Mol Biol 91: 59-66.
98. Yang Z, Korg B, Mossier DM, Zhang X (2011) TLRs, macrophages, and NK cells: Our understandings of their functions in uterus and ovary. Int Immunopharmacol 11: 1442-1450.
99. Katayama ML, Federico MH, Brentani RR, Brentani MM (1998) Eosinophil accumulation in rat uterus following estradiol administration is modulated by laminin and its integrin receptors. Cell Adhes Commun 5: 409-424.
100. Tchernitchin AN, Barrera J, Arroyo P, Mena MA, Vilches K, et al. (1985) Progesterone, but not estradiol, increases TNF-alpha secretion in U937 monocytes. Cytokine 26: 17: 1381-1390.
101. Theoharides TC, Dimitriadou V, Letourneau R, Rozniecki JJ, Vlalogofis H, et al. (1993) Synergistic action of estradiol and myelin basic protein on mast cell secretion and brain myelin changes resembling early stages of demyelination. Neuroscience 57: 861-871.
102. Vlalogofis H, Dimitriadou T, Boucher W, Rozniecki JJ, Correia I, et al. (1992) Estradiol augments while tamoxifen inhibits rat mast cell secretion. Int Arch Allergy Appl Immunol 93: 192-197.
103. Tinetti AN, Barrera J, Arroyo P, Mena MA, Vilches K, et al. (1985) Progesterone, but not estradiol, increases TNF-alpha secretion in U937 monocytes. Cytokine 26: 17: 1381-1390.
105. Vasiadi M, Hliagoftis H, Dimitriadou V, Theoharides TC (1990) Progesterone triggers mast cell secretion. Int J Immunopharmacol Pharmacol 19: 787-794.

106. Villeggiotti H, Dimiridakou V, Theoharides TC (1990) Progesterone triggers mast cell secretion of 5-hydroxytryptamine. Int Arch Allergy Appl Immunol 93: 113-119.

107. Selles J, Polini N, Alvarez C, Massheimer V (2001) Progesterone and 17 beta-estradiol acutely stimulate nitric oxide synthase activity in rat aorta and inhibit platelet aggregation. Life Sci 69: 815-827.

108. Liedman R, Hansson SR, Howe D, Igdibashian S, McLeod A, et al. (2008) Reproductive hormones in plasma over the menstrual cycle in primary dysmenorrhea compared with healthy subjects. Gynecol Endocrinol 24: 508-513.

109. Ma H, Hong M, Duan J, Liu P, Fan X, et al. (2013) Altered cytokine gene expression in peripheral blood monocytes across the menstrual cycle in primary dysmenorrhea: A case-control study. PLoS One 8: e55200.

110. Evans J, Kaitu‘u-Lino T, Salamonsen LA (2011) Extracellular matrix dynamics in scar-free endometrial repair: Perspectives from mouse in vivo and human in vitro studies. Biol Reprod 85: 511-523.

111. Rakoff-Nahoum S, Paglino J, Esami-Varzaneh F, Edberg S, Medzhiltov R (2004) Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 118: 229-241.

112. Janeway CA, Medzhitov R (2002) Innate immune recognition. Annu Rev Immunol 20: 197-216.

113. Akira S, Uematsu S, Takeuchi O (2006) Pathogen recognition and innate immunity. Cell 124: 783-801.

114. Girling JE, Hedger MP (2007) Toll-like receptors in the gonads and reproductive tract: Function and immune regulation. Best Pract Res Clin Obstet Gynaecol 21: 347-354.

115. Andrews WW, Goldenberg RL, Hauth JC, Cliver SP, Conner M, et al. (2005) Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 118: 229-241.

116. Pelzer ES, Allan JA (2012) The isolation and identification of microorganisms in the reproductive environment: The potential impact on the IFV culture system and on IFV outcomes. Journal of Clinical Embryology 15: 44-53.

117. Santiago GL, Tercy I, Verstraeten H, Verhelst R, Trug M, et al. (2012) Longitudinal qPCR study of the dynamics of L. crispatus, L. iners, A. vaginalis, (sialidase positive) G. vaginalis and P. bivia in the vagina. PLoS One 7: e45281.

118. Verhelst R, Verstraeten H, Claeys G, Verschraegen G, Van Simaeys L, et al. (2005) Comparison between Gram stain and culture for the characterization of vaginal microflora: Definition of a new grade that resembles grade I microflora and revised categorization of grade I microflora. BMC Microbiol 5: 61.

119. Witkin SS, Linhares IM, Giraldo P (2007) Bacterial flora in the female genital tract: Function and immune regulation. Best Pract Res Clin Obstet Gynaecol 21: 347-354.

120. Ravel J, Gajjar P, Abdo Z, Schneider GM, Koenig SS, et al. (2011) Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci U S A 108 Suppl 1: 4680-4687.

121. Brotman RM, Ravel J, Bavoli PM, Gravitt PE, Ghanem KG (2010) Microbiome, sex hormones and immune responses in the reproductive tract: Challenges for vaccine development against sexually transmitted infections. Vaccine 11: 252-259.

122. Hickey RJ, Zhou X, Pierson JD, Ravel J, Forney LJ (2012) Understanding vaginal microbiome complexity from an ecological perspective. Transl Res 160: 267-282.

123. Douthitt B, Douthitt A, Schindel S, Langermann T, Strickland J, et al. (2010) Vaginal microbiome complexity from an ecological perspective. Transl Res 160: 267-282.

124. Human Microbiome Project Consortium (2012) Structure, function and diversity of the healthy human microbiome. Nature 486: 207-214.

125. Ferrer M, Ruiz A, Lanza F, Haange S-B, Oberbach A, et al. (2013) Microbiota from the distal guts of lean and obese adolescents exhibit partial functional redundancy besides clear differences in community structure. Environmental Microbiology 15: 211-226.

126. Bhavsar AP, Gutman JA, Finlay BB (2007) Manipulation of host-cell pathways by bacterial pathogens. Nature 449: 827-834.

127. Häcker G, Fisher SF (2002) Bacterial anti-apoptotic activities. FEMS Microbiol Lett 211: 1-6.

128. Ulett GC, Adderson EE (2006) Regulation of apoptosis by gram-positive bacteria: Mechanistic diversity and consequences for immunity. Curr Immunol Rev 2: 119-141.

129. Savill J, Fadok V (2000) Corpse clearance defines the meaning of cell death. Nature 407: 784-788.

130. Gao L, Kwai XA (2000) The modulation of host cell apoptosis by intracellular bacterial pathogens. Trends Microbiol 8: 306-313.

131. Yan F, Polk DB (2002) Probiotic bacterium prevents cytokine-induced apoptosis in intestinal epithelial cells. J Biol Chem 277: 50959-50965.

132. Nougayrède JP, Homburg S, Taieb F, Boury M, Brzuszkiwicz E, et al. (2006) Escherichia coli induces DNA double-strand breaks in eukaryotic cells. Science 313: 848-851.

133. Motveaseli E, Shizarad M, Akrami SM, Moussavi AS, Mirsalehian A, et al. (2013) Normal and tumor cervical cells respond differently to vaginal lactobacilli, independent of pH and lactate. J Med Microbiol 5: 69-72.

134. Santiago GL, Cools P, Verstraeten H, Trug M, Missine G, et al. (2011) Longitudinal study of the dynamics of vaginal microflora during two consecutive menstrual cycles. PLoS One 6: e28180.

135. Larsen B, Monif GR (2001) Understanding the bacterial flora of the female genital tract. Clin Infect Dis 32: e69-77.

136. Swidsinski A, Dörfel Y, Loening-Baucke V, Swidsinski S, Dorffel Y, et al. (2008) An adherent Gardnerella vaginalis biofilm persists on the vaginal epithelium after standard therapy with oral metronidazole. Am J Obstet Gynecol 198: e81-e88.

137. Schillinger J, Mendling W, Loening-Baucke V, Swidsinski S, Dorffel Y, et al. (2008) An adherent Gardnerella vaginalis biofilm persists on the vaginal epithelium after standard therapy with oral metronidazole and factors associated with recurrence. J Infect Dis 193: 1478-1486.

138. Braddock CS, Morton AN, Hocking J, Garland SM, Morris MB, et al. (2006) High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis 193: 1478-1486.

139. Wiesenfeld HC, Hillier SL, Krohn MA, Amortegui AJ, Heine RP, et al. (2002) Lower genital tract infection and endometritis: Insight into subclinical pelvic inflammatory disease. Obstet Gynecol 100: 456-463.

140. Swidsinski A, Verstraeten H, Loening-Baucke V, Swidsinski S, Mendling W, et al. (2013) Presence of a polymicrobial endometrial biofilm in patients with bacterial vaginosis. PLoS One 8: e53997.

141. Jacobsen B, Bernevi P, Chidekel L, Jörgen Platz-Christensen J (2002) Bacterial vaginosis in early pregnancy may predispose for preterm birth and postpartum endometritis. Acta Obstet Gynecol Scand 81: 1006-1010.

142. Kunz G, Beil D, Deininger H, Wittl L, Leyendecker G (1996) The dynamics of rapid sperm transport through the female genital tract: Evidence from vaginal sonography of uterine peristalsis and hysterosalpingoscopy. Hum Reprod 11: 627-632.

143. Kunz G, Beil D, Deininger H, Einspanier A, Mall G, et al. (1997) The uterine peristaltic pump. Normal and impeded sperm transport within the female genital tract. Adv Exp Med Biol 424: 267-277.

144. Parsons JK, Gearhart SL, Gearhart JP (2002) Vaginal reconstruction utilizing sigmoid colon: Complications and long-term results. J Pediatr Surg 37: 629-633.

145.挽救 AS, Mutsaraya M, Mueda DC (1973) Sperm transport from the external cervical os to the fallopian tubes in women: A time and quantitation study. Fertil Steril 24: 655-661.

146. Viniker DA1 (1999) Hypothesis on the role of sub-clinical bacteria of the endometrium (bacteria endometriais) in gynaecological and obstetric enigmas. Hum Reprod Update 5: 373-385.

147. Andrews WW, Goldenberg RL, Hauth JC, Cliver SP, Conner M, et al. (2005) Endometrial microbiobial colonization and plasma cell endometritis after spontaneous or indicated preterm versus term delivery. Am J Obstet Gynecol 193: 739-745.
Citation: Pelzer ES, Huygens F, Beagley KW (2016) Steroid Hormone Dependent Inflammation and Regulation in the Endometrium in Women with Dysfunctional Menstrual Cycles: Is There a Role for Toll-Like Receptor Activation via PAMPs and DAMPs? J Microb Biochem Technol 8: 344-357. doi: 10.4172/1948-5948.JMBT.1000307
Induction of anti-progesterone immunity and pregnancy blocking by anti-progesterone anti-idiotypes. Variable efficacy of polyclonal Ab2 antibodies directed against a panel of closely related Ab1 antibodies. Immunology 73: 348-355.

193. Bukulmez O, Arici A (2000) Leukocytes in ovarian function. Hum Reprod Update 6: 1-15.

194. Alpizar E, Spicer LJ (1994) Effects of interleukin-6 on proliferation and follicle-stimulating hormone-induced estradiol production by bovine granulosa cells in vitro: dependence on size of follicle. Biol Reprod 50: 38-43.

195. Critchley HO, Kelly RW, Brenner RM, Baird DT (2003) Antiprogestins as a model for progesterone withdrawal. Steroids 68: 1061-1068.

196. Geva E, Lessing JB, Lerner-Geva L, Azem F, Yovel I, et al. (1997) Interleukin-10 in preovulatory follicular fluid of patients undergoing in-vitro fertilization and embryo transfer. Am J Reprod Immunol 37: 187-190.

197. Norman RJ, Brännström M (1996) Cytokines in the ovary: Pathophysiology and potential for pharmacological intervention. Pharmacol Ther 69: 219-236.

198. Imai T, Kurachi H, Adachi K, Adachi H, Yoshimoto Y, et al. (1995) Changes in epidermal growth factor receptor and the levels of its ligands during menstrual cycle in human endometrium. Biology of Reproduction 52: 928-938.

199. Smith OP, Jabbour HN, Critchley HO (2007) Cyclooxygenase enzyme expression and E series prostaglandin receptor signalling are enhanced in heavy menstruation. Hum Reprod 22: 1450-1456.

200. Sangha RK, Li XF, Shams M, Ahmed A (1997) Fibroblast growth factor receptor-1 is a critical component for endometrial remodeling: Localization and expression of basic fibroblast growth factor and FGF-R1 in human endometrium during the menstrual cycle and decreased FGF-R1 expression in menorrhagia. Lab Invest 77: 389-402.

201. Harel Z (2008) Dysmenorrhea in adolescents and young adults: From pathophysiology to pharmacological treatments and management strategies. Expert Opin Pharmacother 9: 2661-2672.

202. Xu X, Chen X, Li Y, Cao H, Shi C, et al. (2013) Cyclooxygenase-2 regulated by the nuclear factor-kappa B pathway plays an important role in endometrial breakdown in a female mouse menstrual-like model. Endocrinology 154: 2900-2911.

203. Mihm M, Gangooly S, Muttukrishna S (2011) The normal menstrual cycle in women. Anim Reprod Sci 124: 229-236.

204. Maybin J, Critchley H (2009) Repair and regeneration of the human endometrium. Expert Review of Obstetrics & Gynecology 4: 283-298.

205. Maybin JA, Hirani N, Brown P, Jabbour HN, Critchley HO (2011) The regulation of vascular endothelial growth factor by hypoxia and prostaglandin F(2) alpha during human endometrial repair. J Clin Endocrinol Metab 96: 2475-2483.

206. Li T, Li YG, Pu DM (2006) Matrix metalloproteinase-2 and -9 expressions correlated with angiogenesis in human adenomyosis. Gynecol Obstet Invest 62: 229-235.

OMICS International: Open Access Publication Benefits & Features

Unique features:
- Increased global visibility of articles through worldwide distribution and indexing
- Showcasing recent research output in a timely and updated manner
- Special issues on the current trends of scientific research

Special features:
- 70+ Open Access Journals
- 5,000+ editorial team
- Rapid peer review process
- Quality and quick editorial, review and publication processing
- Indexing at major indexing services
- Sharing Option: Social Networking Enabled for better prominence and citations
- Authors, Reviewers and Editors rewarded with online Scientific Credits
- Best discounts for your subsequent articles

Submit your manuscript at: http://www.editorialmanager.com/jmbt

Citation: Pelzer ES, Huygens F, Beagley KW (2016) Steroid Hormone Dependent Inflammation and Regulation in the Endometrium in Women with Dysfunctional Menstrual Cycles: Is There a Role for Toll-Like Receptor Activation via PAMPs and DAMPs? J Microb Biochem Technol 8: 344-357. doi: 10.4172/1948-5948.1000307